Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and Toxicity

Drs Kathy D. Miller and Sara M. Tolaney discuss advancements and considerations for optimizing treatment for HER2-positive breast cancer, focusing on balancing efficacy with minimizing toxicity.
Relevant disclosures can be found with the episode show notes on Medscape www.medscape.c.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
Resources
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer pubmed.ncbi.nl...
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer: Final 10-Year Analysis of the Open-Label, Single-Arm, Phase 2 APT Trial pubmed.ncbi.nl...
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer pubmed.ncbi.nl...
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial pubmed.ncbi.nl...
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT pubmed.ncbi.nl...
Treatment Discontinuation, Patient-Reported Toxicities and Quality-of-Life by Age Following Trastuzumab Emtansine or Paclitaxel/Trastuzumab (ATEMPT) pubmed.ncbi.nl...
ATEMPT 2.0: Adjuvant T-DM1 vs TH clinicaltrials...
Neoadjuvant Treatment With HER2-Targeted Therapies in HER2-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis pubmed.ncbi.nl...
5-Year Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients With Locally Advanced, Inflammatory, or Early-Stage HER2-Positive Breast Cancer (NeoSphere): A Multicentre, Open-Label, Phase 2 Randomised Trial pubmed.ncbi.nl...
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy clinicaltrials...
Alliance A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + Tucatinib/Placebo in Patients With Residual HER2-Positive Invasive Breast Cancer pubmed.ncbi.nl...
Incidence of Interstitial Lung Disease and Cardiotoxicity With Trastuzumab Deruxtecan in Breast Cancer Patients: A Systematic Review and Single-Arm Meta-Analysis pubmed.ncbi.nl...
STOP-HER2: Stopping Trastuzumab in HER2+ MBC clinicaltrials...